Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Metformin May Delay Aging and Cancer Progression

Metformin delays aging and cancer progression by reducing the production of....
Advertisement

A research team from the University of Montreal revealed the mechanism of how metformin slows aging and cancer progression. In a study, they found that metformin reduces the production of inflammatory cytokines. These inflammatory cytokines are key players activating the immune system in tissue damage during aging and tumor growth in cancer development.

Dr. Gerardo Ferbeyre and colleagues found that metformin decreases cytokines by disrupting a protein called NF-kB that would normally trigger cytokine activation and the immune system. When cytokines are overproduced, this leads to pathological inflammation that is involved in both the aging and cancer processes.

Dr. Ferbeyre said, "This is an important finding with implications for our understanding on how the normal organism defends itself from the threat of cancer and how a very common and safe drug may aid in treatment of some cancers and perhaps slow down the aging process." He added, "It remains that determining the specific targets of metformin would give us an even better opportunity of profit from its beneficial effects. That's what we want to figure out next." This finding may be an important step in finding a place for metformin therapy in anti-cancer and anti-aging therapy.

"Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-B activation" Aging Cell, March 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 05 April, 2013 and appeared in  MedicationAging & DiabetesOncologyInsulinIssue 671

Past five issues: Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 | GLP-1 Special Editions August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
HbA1c Increases with Age
Posted August 01, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014
Statin Adherence Linked to New Onset Diabetes Risk
Posted July 25, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you recommend SGLT-2 drugs for type 1 diabetes?
CME/CE of the Week
Jeffrey Mechanick

Category: General Diabetes
Credits: .75
Search Articles On Diabetes In Control